4.7 Review

Stem-cell based organ-on-a-chip models for diabetes research

期刊

ADVANCED DRUG DELIVERY REVIEWS
卷 140, 期 -, 页码 101-128

出版社

ELSEVIER
DOI: 10.1016/j.addr.2018.10.010

关键词

Type 1 diabetes; Type 2 diabetes; HiPSCs; Human in vitro model; Organ-on-a-chip; Multi-organ chips; Microfluidics

资金

  1. Fraunhofer-Gesellschaft internal programs [601543]
  2. European Union [645991-2, 766884]

向作者/读者索取更多资源

Diabetes mellitus (DM) ranks among the severest global health concerns of the 21st century. It encompasses a group of chronic disorders characterized by a dysregulated glucose metabolism, which arises as a consequence of progressive autoimmune destruction of pancreatic beta-cells (type 1 DM), or as a result of beta-cell dysfunction combined with systemic insulin resistance (type 2 DM). Human cohort studies have provided evidence of genetic and environmental contributions to DM; yet, these studies are mostly restricted to investigating statistical correlations between DM and certain risk factors. Mechanistic studies, on the other hand, aimed at re-creating the clinical picture of human DM in animal models. A translation to human biology is, however, often inadequate owing to significant differences between animal and human physiology, including the species-specific glucose regulation. Thus, there is an urgent need for the development of advanced human in vitro models with the potential to identify novel treatment options for DM. This review provides an overview of the technological advances in research on DM-relevant stem cells and their integration into microphysiological environments as provided by the organ-on-a-chip technology. (C) 2018 The Authors. Published by Elsevier B.V.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据